A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...
The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for ...
Intellia Therapeutics’ CRISPR-based therapy lonvoguran ziclumeran reduced hereditary angioedema attacks by 87% in a pivotal ...
Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news ...
The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial ...
Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...
Intellia’s CEO said that the trial marks the first positive Phase III readout for an in vivo CRISPR gene therapy.
Hosted on MSN
Intellia seeks FDA nod after phase 3 CRISPR success
Intellia Therapeutics has begun a rolling FDA submission for lonvoguran ziclumeran (lonvo-z) after its phase 3 trial showed an 87% reduction in hereditary angioedema attacks versus placebo. The ...
CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.
A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.
Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results